Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216846 · ClinicalTrials.gov registry record · NA
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
A NA study of Fall and Adverse Drug Events, sponsored by Florida Atlantic University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07216846 is a NA study of Fall and Adverse Drug Events that is actively recruiting participants, run by Florida Atlantic University. The registered enrollment target is 1,000 participants, below the 1,255-participant average among 19 other Fall trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07216846, a NA study of Fall and Adverse Drug Events, is actively recruiting participants, sponsored by Florida Atlantic University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications. The main questions it aims to answer are: * Can DNA-based prescribing reduce medication-related side effects, especially falls and fall-related injuries? * Does providing pharmacogenomic results to primary care physicians improve medication safety compared with usual care? Researchers will compare two groups: 1. DNA Care Pathway: Physicians receive patients' DNA results to guide prescribing. 2. Emergency Department Care Pathway: Physicians provide usual care; DNA results are shared only after study completion. Participants will: * Provide a cheek swab sample for DNA analysis (1 minute). * Receive monthly follow-up phone calls for 6 months to track falls, injuries, medication changes, and side effects. * Complete a fall and medication calendar. * Allow researchers to review primary care physician medical records for study outcomes. Approximately 1,000 participants will take part, with follow-up lasting about 6-7 months.
Conditions Studied
Interventions
- OTHER DNA care pathway
Study Locations (1)
Florida
- Delray Medical Center - Delray Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216846
The ClinicalTrials.gov registry entry for NCT07216846 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,255-participant average among 19 other Fall trials with a reported enrollment target (20% lower). The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Fall appearing as the primary indexed condition, and to 1 intervention - of which DNA care pathway is the first listed.
NCT07216846 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07216846 about?
NCT07216846 is a clinical study titled "The Geriatric Emergency Department Pharmacologic Harm Prevention Project". The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications. The main questions it aims to answer are: * Can DNA-based prescribing reduce medicati...
What is the current status of trial NCT07216846?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2026-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT07216846 study?
This clinical trial studies the following conditions: Fall, Adverse Drug Events, Pharmacogenomic Drug Interaction, Poly Pharmacy, Pharmacogenomic Testing.
What interventions are being tested in trial NCT07216846?
The interventions under investigation include: DNA care pathway (OTHER).
Who is sponsoring clinical trial NCT07216846?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216846 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fall
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing a Technology-based Body and Mind Intervention
RECRUITING · NA
-
Comparison of Smartphone and Community-Based Delivery of the Otago Exercise Program for Fall Risk in Older Adults
RECRUITING · NA
-
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
RECRUITING · NA
-
Real-life Dual-Task Training
RECRUITING · NA
-
Exercise Program for Deaf Seniors to Increase Their Balance and Fitness
ACTIVE NOT RECRUITING · NA
-
COcoa Supplement and Multivitamin Outcomes Study: Effects on Falls and Physical Performance
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.